Evidence map›Paper›PMID 38929965›Full record

ArticleJournal of clinical medicine2024

Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer.

Jamaal C Jackson, Darren Sanchez, Andrew C Johns, Matthew T Campbell, Ahmet M Aydin, Neriman Gokden, Sanjay Maraboyina, Jason L Muesse, John F Ward, Louis L Pisters and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jamaal C JacksonDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Darren SanchezDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0009-0001-8463-7644
Andrew C JohnsDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Matthew T CampbellDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-1915-4491
Ahmet M AydinDivision of Urology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.ORCID 0000-0002-6047-8431
Neriman GokdenDivision of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Sanjay MaraboyinaDivision of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Jason L MuesseDepartment of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
John F WardDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6027-8774
Louis L PistersDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Niki M ZachariasDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Charles C GuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shi-Ming TuDivision of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Germ cell tumor of the testis (GCT) is a curable cancer even when it is widely metastatic; however, outcomes can differ based on tumor histology. Chemo-resistance in certain phenotypes, such as teratoma and yolk sac tumor, contributes to poor clinical outcomes in some patients with GCT. Despite this resistance to S-YSTemic therapy, many of these tumor subtypes remain amenable to surgical resection and possible cure. In this study, we report on a series of seven patients highlighting two chemo-resistant subtypes of nonseminomatous germ cell tumor (NSGCT), sarcomatoid yolk sac tumor (S-YST), and epithelioid trophoblastic tumor (ETT) for which early resection rather than additional salvage chemotherapy or high-dose intense chemotherapy might provide a superior clinical outcome and enhance cure rate.

Indexed as

drug resistanceepithelioid trophoblastic tumorintratumoral heterogeneitysarcomatoid yolk sac tumorsomatic transformationtesticular cancertherapy development

Identifiers

PMID38929965
PMCPMC11205088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.